scholarly journals Application of human immunodeficiency virus type 1 BED enzyme immunoassay on dried blood spots in India

2009 ◽  
Vol 58 (3) ◽  
pp. 312-317 ◽  
Author(s):  
Vemu Lakshmi ◽  
Talasila Sudha ◽  
Rakhi Dandona ◽  
Vijay D. Teja ◽  
G. Anil Kumar ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Enzyme Immunoassay ◽  
Incidence Rate ◽  
Dried Blood Spots ◽  
Population Based ◽  
Annual Incidence ◽  
Hiv Incidence ◽  
Blood Spots ◽  
Immunodeficiency Virus ◽  
Hiv 1

Dried blood spots (DBSs) on filter paper are being used increasingly in population-based human immunodeficiency virus (HIV) studies. This study evaluated the application of a BED enzyme immunoassay (EIA) on DBSs to estimate HIV incidence in a population-based study in India. The Calypte HIV-1 BED Incidence EIA was performed on 224 HIV-1-positive DBS samples, after screening 12 617 individuals from a population-based sample in Guntur district in the southern Indian state of Andhra Pradesh. The number of recently infected HIV cases was identified using this BED assay and was used to estimate the annual HIV incidence rate based on calculations and adjustment formulae suggested by the Centers for Disease Control and Prevention (CDC). The updated BED data management software provided by the CDC was used for analyses. Of the 224 HIV-1 antibody-positive DBS samples, 29 (12.95 %) were estimated by the BED HIV-1 assay to have been infected within the past 155 days. After adjusting for age, gender and rural/urban distribution of the population, the annual incidence rate of HIV-1 infection was estimated to be 0.32 % (95 % confidence interval 0.20–0.44 %). This annual incidence was 18.6 % of the HIV prevalence of 1.72 % in this study. Thus, the BED assay revealed a higher incidence of HIV in this study than was expected from the prevalence. Correlation of the BED assay with panel testing and longitudinal incidence data in the Indian population is needed to calibrate it for use in India.

scholarly journals Stability of Human Immunodeficiency Virus Serological Markers in Samples Collected as HemaSpot and Whatman 903 Dried Blood Spots

2018 ◽  
Vol 56 (10) ◽  
Author(s):  
Mark M. Manak ◽  
Holly R. Hack ◽  
Ashley L. Shutt ◽  
Brook A. Danboise ◽  
Linda L. Jagodzinski ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Western Blot ◽  
Dried Blood Spots ◽  
Early Infection ◽  
Blood Collection ◽  
Signal Recovery ◽  
Sample Collection ◽  
Blood Spots ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACTDried blood spots (DBS) are frequently used in clinical testing for biosurveillance, infectious disease and confirmatory testing, and clinical trials, particularly for populations in remote areas. The HemaSpot-HF blood collection device (HS) provides an alternative format to the Whatman 903 cards (903) to simplify sample collection and processing. In this study, the performance of the HS was compared to that of the 903 using previously characterized clinical specimens and HIV seroconversion panels known to exhibit markers of early human immunodeficiency virus (HIV) infection. HS and 903 samples were prepared and tested by Bio-Rad GS HIV Combo Ag/Ab enzyme immunoassay (EIA), GS HIV-1/-2 Plus O EIA, GS HIV-1 Western blot, and HIV-1 Geenius assays. Both HS and 903 performed well for up to 6 months at room temperature, but a marked loss of Western blot and low titer antibody signals from early infection samples was observed in samples stored for 180 days at elevated (37 to 45°C) temperatures and high humidity (95%). HemaSpot samples placed in sealed bags with additional desiccant were protected from degradation and showed improved signal recovery relative to that of the 903. HS was easier to use than the 903 and showed higher sensitivity and reproducibility for early infection samples and improved stability.

PCR of DNA from dried blood spots on filter paper coupled to a simple DNA enzyme immunoassay for rapid detection of HIV-1

1996 ◽  
Vol 52 (4) ◽  
pp. 308-309
Author(s):  
B. Schweiger ◽  
C. Kücherer ◽  
C. Fleischer ◽  
H. v. Spreckelsen ◽  
P. Zablocki-Kaiser ◽  
...  
Keyword(s):  
Enzyme Immunoassay ◽  
Filter Paper ◽  
Rapid Detection ◽  
Dried Blood Spots ◽  
Blood Spots ◽  
Dna Enzyme Immunoassay ◽  
Hiv 1

scholarly journals Detection of IgG3 antibodies specific to the human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired infection

2018 ◽  
Vol 146 (10) ◽  
pp. 1293-1300 ◽  
Author(s):  
I. F. T. Viana ◽  
D. F. Coêlho ◽  
M. L. Palma ◽  
E. J. M. Nascimento ◽  
G. Gu ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Control Strategies ◽  
Hiv Incidence ◽  
Recent Infection ◽  
Immunodeficiency Virus ◽  
P24 Protein ◽  
Hiv 1

AbstractReducing the risk of human immunodeficiency virus type 1 (HIV-1) transmission is still a public health priority. The development of effective control strategies relies on the quantification of the effects of prophylactic and therapeutic measures in disease incidence. Although several assays can be used to estimate HIV incidence, these estimates are limited by the poor performance of these assays in distinguishing recent from long-standing infections. To address such limitation, we have developed an assay to titrate p24-specific IgG3 antibodies as a marker of recent infection. The assay is based on a recombinant p24 protein capable to detect total IgG antibodies in sera using a liquid micro array and enzyme-linked immunosorbent assay. Subsequently, the assay was optimised to detect and titrate anti-p24 IgG3 responses in a panel of sequential specimens from seroconverters over 24 months. The kinetics of p24-specific IgG3 titres revealed a transient peak in the 4 to 5-month period after seroconversion. It was followed by a sharp decline, allowing infections with less than 6 months to be distinguished from older ones. The developed assay exhibited a mean duration of recent infection of 144 days and a false-recent rate of ca. 14%. Our findings show that HIV-1 p24-specific IgG3 titres can be used as a tool to evaluate HIV incidence in serosurveys and to monitor the efficacy of vaccines and other transmission control strategies.

Sign in / Sign up

Export Citation Format

Share Document